PTK2 and adenocarcinoma: FAK pharmacological inhibitors are being investigated as cancer chemotherapeutics and FAK inhibition has been shown to ameliorate tumor growth, metastasis, and angiogenesis in mouse models of adenocarcinoma, ovarian carcinoma, pancreatic cancer, and non-small lung cancer (Halder et al., 2007; Slack-Davis et al., 2009; Lane et al., 2010; Stokes et al., 2011; Chen et al., 2012; Jean et al., 2014).